From Leo's presentation 9/11: "Our research

From Leo's presentation 9/11:

"Our research showed Prurisol most definitely and clearly outperform Methatrexate, a standard of cure treatment for advanced psoriasis as there was no recurrence of psoriasis on the animals. Visually, it eliminated all indications of psoriasis. You can clearly see the results on your screen here or on our website. The recent activity of GlaxoSmithKline spending approximately 350 million dollars to acquire rights to a Phase 2 topical psoriasis treatment demonstrates how valuable and in high demand new dermatological drugs are right now. We feel that our oral therapy is far greater value and will be at the same clinical stage in 2013. We are advancing Prurisol immediately into mid to late stage clinical trials based on the fact that the active moiety of Prurisol has already received US Food & Drug Administration approval. After meeting with the FDA in June regarding the regulatory pathway for Prurisol, the agency informed us that a 505B2 application would be an acceptable approach for the new drug candidate. With that guidance from the FDA, we are now moving forward with planning the first Phase 2 clinical trial for Prurisol. "